Media coverage about Innoviva (NASDAQ:THRX) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Innoviva earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.5344915597354 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Innoviva (THRX) remained flat at $9.81 during mid-day trading on Tuesday. Innoviva has a 12-month low of $6.36 and a 12-month high of $21.16. The stock’s 50 day moving average price is $9.81 and its 200 day moving average price is $11.67.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://sportsperspectives.com/2017/10/10/innoviva-thrx-receiving-somewhat-favorable-news-coverage-report-shows.html.
Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).
Receive News & Ratings for Innoviva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc and related companies with MarketBeat.com's FREE daily email newsletter.